Insmed Quarterly Revenue Jumps 268% to $524.4 Million, Guidance Raised

what happened

According to TradingView, citing the company's SEC filing, Insmed posted third-quarter 2026 revenue of $524.4 million, more than three times the $142.3 million of a year earlier. The net loss narrowed to $100.3 million, or $0.46 per share, from $370.0 million, or $1.75 per share, a year ago.

BRINSUPRI brought in $400.1 million and ARIKAYCE $124.4 million. Management raised full-year revenue forecasts for both drugs: BRINSUPRI now $1.35–1.4 billion, ARIKAYCE $460–470 million. Japan approved BRINSUPRI for NCFB patients, and the launch there began in October. Cash and investments stood at about $1.1 billion at the end of September.

The FDA accepted an ARIKAYCE supplemental application for Priority Review in MAC lung disease, with a target action date of January 28, 2027.

why it matters

Strong top-line growth and a higher outlook point to rising commercial uptake of the company's two marketed drugs, the main driver investors are watching. The roughly $1.1 billion cash position and ongoing TPIP development add to the picture, but the quarterly operating loss shows the business is not yet profitable at the operating line.

market impact

Insmed shares: strong revenue and a higher outlook support sentiment toward the stock

• ▲Insmed shares pressure up — raised 2026 revenue guidance and fast sales growth of its two drugs

tags

instruments